Values First Advisors Inc. Sells 3,186 Shares of Agenus Inc. (NASDAQ:AGEN)

Values First Advisors Inc. trimmed its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 19.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,894 shares of the biotechnology company’s stock after selling 3,186 shares during the quarter. Values First Advisors Inc.’s holdings in Agenus were worth $35,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in AGEN. Walleye Capital LLC purchased a new stake in Agenus in the third quarter worth about $1,003,000. BNP Paribas Financial Markets lifted its stake in Agenus by 2,271.5% in the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 37,866 shares during the period. Geode Capital Management LLC lifted its stake in Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares during the period. FMR LLC lifted its stake in Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 27,309 shares during the period. Finally, Barclays PLC lifted its stake in Agenus by 295.3% in the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 20,777 shares during the period. 61.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Agenus Stock Performance

AGEN stock opened at $3.50 on Friday. The firm has a market cap of $82.11 million, a price-to-earnings ratio of -0.31 and a beta of 1.31. The firm has a 50-day simple moving average of $3.26 and a two-hundred day simple moving average of $4.18. Agenus Inc. has a one year low of $2.50 and a one year high of $19.69.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.